Article Versions Notes

Fingrut W, Davis W, McGinnis E, Dallas K, Ramadan K, Merkeley H, Leitch H, Abou Mourad Y, Cassaday RD, Ross C, et al. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? Current Oncology. 2021; 28(1):252-259. https://doi.org/10.3390/curroncol28010027

Fingrut, Warren, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, and et al. 2021. "Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?" Current Oncology 28, no. 1: 252-259. https://doi.org/10.3390/curroncol28010027

Fingrut, W., Davis, W., McGinnis, E., Dallas, K., Ramadan, K., Merkeley, H., Leitch, H., Abou Mourad, Y., Cassaday, R. D., Ross, C., & Léger, C. (2021). Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? Current Oncology, 28(1), 252-259. https://doi.org/10.3390/curroncol28010027